We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Monday
May 05
15:15 - 16:15
Business 1-2
Brachytherapy 1
Laura Motisi, Switzerland;
Taran Paulsen Hellebust, Norway
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.
Mini-Orals
Brachytherapy
Gynaecology / Urology
15:00 - 15:07
Survival and toxicity outcomes of perioperative high-dose-rate brachytherapy in soft tissue sarcomas of the extremities and superficial trunk.
LIDIA GOMEZ PEREA, Spain
E25-3851
15:07 - 15:14
Automating development of MDR-compliant patient-tailored 3D printed cervical cancer brachytherapy applicators
Robin Straathof, The Netherlands
E25-4502
15:14 - 15:21
Application of Polyethylene Glycol Hydrogel in Concurrent Chemoradiotherapy for Cervical Cancer to Prevent Radiation-induced Rectal Injury
Junfang Yan, China
E25-3160
15:21 - 15:28
Temporal Drift in Ir-192 source strength measurements. A BRAPHYQS Multi-center analysis
Javier Vijande, Spain
E25-1200
15:28 - 15:35
Discrepancy between measured Ir-192 HDR source strength and manufacturer source certificate in sites across Australia, New Zealand and the UK
Paul Simpson, Australia
E25-1328
15:35 - 15:42
Long-term outcomes of LDR brachytherapy plus EBRT in prostate cancer: Influence of androgen deprivation therapy on disease progression and toxicity
Alai Goñi Ramirez, Spain
E25-141
15:42 - 15:49
Long-term outcomes of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer: A multicentered retrospective analysis
Wiwatchai Sittiwong, Thailand
E25-3807
15:49 - 15:56
Interstitial brachytherapy for early oral cavity squamous cell carcinoma: long-term treatment outcomes from a single tertiary oncology centre
Hing Yee Wong, China, Hong Kong Special Administrative Region
E25-2782